Interplay of Epigenetics with Gynecological Cancer

Bleoţu, Coralia; Socolov, Demetra; Antón, María M.; Botezatu, A.; Iancu, Iulia Virginia; Braşoveanu, Lorelei Irina; GabrielaAnton,; Diaconu, Carmen C.

doi:10.5772/61032

Cited by 2 publications

(3 citation statements)

References 315 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant DNA methylation and the overexpression of the BRCA2, NFKB1, CTGF, and BCL3 genes involved in cell proliferation have been found in ovarian cancer [ 249 ].…”

Section: Egcg Treatment In Malignant Gynecological Diseasesmentioning

confidence: 99%

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

Włodarczyk,

Ciebiera,

Nowicka

et al. 2024

Nutrients

View full text Add to dashboard Cite

The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.

show abstract

“…Aberrant DNA methylation and the overexpression of the BRCA2, NFKB1, CTGF, and BCL3 genes involved in cell proliferation have been found in ovarian cancer [ 249 ].…”

Section: Egcg Treatment In Malignant Gynecological Diseasesmentioning

confidence: 99%

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

Włodarczyk,

Ciebiera,

Nowicka

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…Epigenetic mechanisms (DNA methylation, histone modifications and nucleosome remodeling) have been shown to represent the prevalent carcinogenetic player [ 35 ]. Epigenetics involves the role of non-coding RNAs (including microRNAs), that by regulating gene expression of their target genes, they may lead to their inhibition and/or degradation [ 36 ].…”

Section: Challengesmentioning

confidence: 99%

“…Epigenetic silencing has been suggested as one of the major causes of gynecologic cancer, being able to inactivate multiple pathways such as cell cycle control, DNA repair, and apoptosis [ 36 ]. Epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, and monitoring of diseases, as well as may represent novel therapeutic targets [ 37 , 38 ].…”

Section: Challengesmentioning

confidence: 99%

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Fiore

Suleiman

Ellul

et al. 2021

Cancers

View full text Add to dashboard Cite

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on expert opinion, retrospective studies, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges through the creation of a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide.

show abstract

Interplay of Epigenetics with Gynecological Cancer

Cited by 2 publications

References 315 publications

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Contact Info

Product

Resources

About